Fresh Equities
Raises
Research
About
Looking for more information?

Contact our responsive and friendly client services team any time.

CLINUVEL PHARMACEUTICALS LIMITED

INVESTOR PRESENTATION - CLINUVEL PHARMACEUTICALS LIMITED

ASX:CUV

CLINUVEL PHARMACEUTICALS LIMITED

Health Care

Clinuvel Pharmaceuticals Limited (CUV) is a biopharmaceutical company focused on developing drugs for the treatment of a range of severe skin disorders. CUV's lead compound is SCENESSE (afamelanotide), a drug targeting erythropoietic protoporphyria (EPP). Former Names EpiTan Limited (EPT),28/02/2006

Read more

Market Cap

$1.01b

Price at Close

$20.42

4w avg. Volume

114.10k

4w avg. Turnover

$2.33m

Announcements
announcementt+2 movementdate
  • Presentation Jefferies Virtual London Healthcare Conference

    Periodic Reports

  • -0.34%

    19 Nov 2020

-0.34%

19 Nov 2020
  • Chair Letter

    Letter To Shareholders

  • -1.65%

    18 Nov 2020

-1.65%

18 Nov 2020
  • Results of Meeting

    Notice Of Meeting

  • -2.07%

    11 Nov 2020

-2.07%

11 Nov 2020
  • Chair Address

    Chairman's Address

  • -2.07%

    11 Nov 2020

-2.07%

11 Nov 2020
  • Managing Directors AGM Presentation

    Chairman's Address

  • -2.07%

    11 Nov 2020

-2.07%

11 Nov 2020
  • CLINUVEL Strategic Update - Executive Summary

    Periodic Reports

  • -6.91%

    29 Oct 2020

-6.91%

29 Oct 2020
  • CLINUVEL Strategic Update - Extended

    Periodic Reports · Market sensitive

  • -6.91%

    29 Oct 2020

-6.91%

29 Oct 2020
  • Appendix 4C - quarterly

    Commitments test entity quarterly reports · Market sensitive

  • -6.91%

    29 Oct 2020

-6.91%

29 Oct 2020
  • Media Release - CLINUVEL to Trial Innovative Drug in Stroke

    Progress Report · Market sensitive

  • -0.93%

    27 Oct 2020

-0.93%

27 Oct 2020
  • afamelanotide for Acute Stroke Patients

    Progress Report

  • -0.93%

    27 Oct 2020

-0.93%

27 Oct 2020
Market Data

Current Price

$20.42

52WK HIGH

$30.17

52WK LOW

$12.92

1YR RETURN

-28.73%

1YR RETURN VS. SECTOR

-44.42%

90 DAY RETURN

-1.78%

ASX RANK

267

/2,026

SECTOR RANK

4

/47

SHARES OUTSTANDING

49.41m
ASX:CUV

CLINUVEL PHARMACEUTICALS LIMITED

Health Care

Clinuvel Pharmaceuticals Limited (CUV) is a biopharmaceutical company focused on developing drugs for the treatment of a range of severe skin disorders. CUV's lead compound is SCENESSE (afamelanotide), a drug targeting erythropoietic protoporphyria (EPP). Former Names EpiTan Limited (EPT),28/02/2006

Read more

Market Cap

$1.01b

Price at Close

$20.42

4w avg. Volume

114.10k

4w avg. Turnover

$2.33m

ASX:CUV is not raising right now

Want to invest?

Fresh Equities

Copyright © 2020 Fresh Equities. All rights reserved. ACN 619 657 028. CAR: 001267539 of AFSL: 471379.

Contact Us

(03) 9028 2888

clients@freshequities.com

Address

Level 7, 388 Bourke St
Melbourne VIC 3000
Australia

Copyright © 2020 Fresh Equities. All rights reserved. ACN 619 657 028. CAR: 001267539 of AFSL: 471379.